Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Quadriderme® in the Treatment of Impetiginous Eczema (Study P05134AM4)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Minimum age: 12 years~* Good general health confirmed by clinical history and a physical and skin examination (excluding area of skin with impetiginous eczema).~* Diagnosis of impetiginous eczema.~* Ability to understand the procedures of the protocol and follow the requirements during the course of the study.~* Results of routine laboratory tests - hemogram with leukogram and platelet count, creatinine, glucose, sed. rate, IgE level and transaminases; along with plasma cortisol and adrenocorticotropic hormone (ACTH) levels prior to the start of the treatment. These results must all be within normal limits or not clinically relevant in order to be included in the trial.~Exclusion Criteria:~* Pregnant participants or women of childbearing age who are not using birth control methods considered reliable by the attending physician.~* Participants with a history of hypersensitivity to any of the components of the medication being studied.~* Participants in whom the extent or severity of the lesions requires treatment of a different type than what is planned for this trial.~* Participants who need any other type of topical or systemic medication during the trial that might affect the course of the disease.~* Participants who have been treated with other topical medications during the 14-day period prior to the start of the trial.~* Participants who have received systemic corticosteroids or any other immunosuppressant medication during the 28-day period prior to the start of the study.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- QUADRIDERME® cream (Type: EXPERIMENTAL): QUADRIDERME® cream (betamethasone diproprionate, clotrimazole, and gentamicin sulfate)
- Betamethasone and Gentamicin (Type: ACTIVE_COMPARATOR): Combination of betamethasone diproprionate cream and gentamicin sulfate cream
- Betamethasone (Type: ACTIVE_COMPARATOR): Betamethasone diproprionate cream

Based on this trial design, predict the completion outcome and termination type (if applicable).